Post by Dicot Pharma AB

Early commercial strategy is key - in today’s biotech landscape, value creation starts far earlier than it used to and many critical decisions are made during early development. For Dicot Pharma, these insights are essential as we advance next-generation erectile dysfunction therapeutics designed to address unmet patient needs.   That’s why we’re pleased that our CEO, Elin Trampe, will join the LSX panel “Early Commercial Strategy: Building Value from Day One.” The discussion will explore how early‑stage companies can integrate commercial thinking into R&D and business development, including when and how to introduce commercial leadership.   If you’re navigating early growth, preparing for your next inflection point, or attending LSX, we invite you to join the conversation and explore how early commercial thinking can unlock stronger, more resilient biotech pipelines. Market Opportunities & Commercialisation (Room 3C + 3D) Wednesday, 25 March 2026 12:10 - 12:50 #lsxeurope #ErectileDysfunction #lifescience #innovation